LifeStance Health Group (NASDAQ:LFST) Upgraded by The Goldman Sachs Group to Buy Rating

The Goldman Sachs Group upgraded shares of LifeStance Health Group (NASDAQ:LFST) from a neutral rating to a buy rating in a research report sent to investors on Monday, MarketBeat Ratings reports. The Goldman Sachs Group currently has $10.00 target price on the stock.

Separately, Barclays upped their price target on shares of LifeStance Health Group from $6.00 to $7.00 and gave the stock an “underweight” rating in a research report on Monday, November 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, LifeStance Health Group has an average rating of “Hold” and an average target price of $8.70.

LifeStance Health Group Stock Performance

NASDAQ LFST opened at $7.75 on Monday. The company has a market capitalization of $2.97 billion, a PE ratio of -29.81 and a beta of 1.28. LifeStance Health Group has a twelve month low of $4.64 and a twelve month high of $9.20. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.19. The business’s 50-day moving average price is $7.19 and its 200 day moving average price is $6.35.

LifeStance Health Group (NASDAQ:LFST) last issued its earnings results on Thursday, November 7th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.05. LifeStance Health Group had a negative return on equity of 6.66% and a negative net margin of 7.90%. The business had revenue of $312.70 million for the quarter, compared to analyst estimates of $302.25 million. During the same period last year, the company posted ($0.17) EPS. The business’s quarterly revenue was up 18.9% on a year-over-year basis. On average, research analysts predict that LifeStance Health Group will post -0.2 earnings per share for the current year.

Insider Activity

In other LifeStance Health Group news, Director Robert Bessler sold 75,000 shares of the firm’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $7.54, for a total transaction of $565,500.00. Following the completion of the transaction, the director now directly owns 1,424,447 shares of the company’s stock, valued at $10,740,330.38. This trade represents a 5.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 6.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. CIBC Asset Management Inc acquired a new stake in LifeStance Health Group during the second quarter worth about $53,000. Algert Global LLC bought a new position in LifeStance Health Group during the 2nd quarter worth $57,000. Victory Capital Management Inc. boosted its holdings in shares of LifeStance Health Group by 27.0% during the second quarter. Victory Capital Management Inc. now owns 14,407 shares of the company’s stock valued at $71,000 after acquiring an additional 3,063 shares during the period. Park Edge Advisors LLC acquired a new position in shares of LifeStance Health Group during the third quarter valued at $73,000. Finally, Townsquare Capital LLC bought a new position in shares of LifeStance Health Group during the third quarter worth about $73,000. Institutional investors own 85.50% of the company’s stock.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.